Plans unveiled today by pharmaceutical company AstraZeneca for its new £330m facility in Cambridge have been welcomed by MedCity, launched by the Mayor of London in April to promote innovation and investment in the Cambridge-London-Oxford golden triangle

Read more from AstraZeneca here.

Kit Malthouse, Deputy Mayor of London for Business and Enterprise and a member of MedCity’s advisory board, says:

“The Cambridge-London-Oxford golden triangle is home to world-leading biomedical science research and development, and it’s vital that universities and industry work hand in hand to translate this excellence into new treatments and medicines as speedily as possible. So I’m delighted that AstraZeneca is making this commitment to Cambridge, which also places it within easy reach of other leading research institutions in London, Oxford and the south east.

“The designs for the new hub demonstrate an open, outward-looking approach that I hope will facilitate collaboration and embed the company firmly in the research community of the golden triangle. This is a move that will strengthen the global competitiveness of the life sciences sector in the UK as a whole.”

Established by the Mayor of London with the capital’s three Academic Health Science Centres – Imperial College Academic Health Centre, King’s Health Partners, and UCL Partners – MedCity brings together the outstanding life sciences strengths of London and the greater south east.

Over the next 20 years, MedCity will position the region as a world-leading, interconnected hub for research, development, manufacturing and commercialisation by championing collaboration and entrepreneurship, promoting a joined up and globally distinct life sciences offer, and providing a visible ‘go-to’ point for industry and investors.